Cargando…
Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report
Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302284/ https://www.ncbi.nlm.nih.gov/pubmed/35866832 http://dx.doi.org/10.1097/MD.0000000000029446 |
_version_ | 1784751602725289984 |
---|---|
author | Gao, Lingsu Li, Dengju Ding, Meiqi |
author_facet | Gao, Lingsu Li, Dengju Ding, Meiqi |
author_sort | Gao, Lingsu |
collection | PubMed |
description | Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfibrinolysis. PATIENT CONCERNS: A 69-year-old man presented with ecchymosis of the right arm and chest wall. DIAGNOSIS: Considering the clinical picture, coagulation function test results, and FXIII activity, the patient was finally diagnosed with hyperfibrinolysis secondary to acquired factor XIII deficiency. INTERVENTIONS: The patient was treated with fresh frozen plasma, aminomethylbenzoic acid, a prothrombin complex, etamsylate, dexamethasone, and cryoprecipitate. OUTCOMES: The patient improved and was discharged after factor replacement therapy, and no further bleeding was reported 1 month after discharge. CONCLUSION: This case report illustrates that the complications of Factor XIII deficiency may include hyperfibrinolysis. Since timely diagnosis of FXIIID is challenging, detailed coagulation factor examinations are needed for definitive diagnosis. It has been suggested that gene testing and antibody testing can help in diagnosis. If ideal treatment is not available, alternative treatment should be provided to reduce bleeding. |
format | Online Article Text |
id | pubmed-9302284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93022842022-08-03 Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report Gao, Lingsu Li, Dengju Ding, Meiqi Medicine (Baltimore) Research Article Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a rare case of idiopathic FXIIID with secondary hyperfibrinolysis. PATIENT CONCERNS: A 69-year-old man presented with ecchymosis of the right arm and chest wall. DIAGNOSIS: Considering the clinical picture, coagulation function test results, and FXIII activity, the patient was finally diagnosed with hyperfibrinolysis secondary to acquired factor XIII deficiency. INTERVENTIONS: The patient was treated with fresh frozen plasma, aminomethylbenzoic acid, a prothrombin complex, etamsylate, dexamethasone, and cryoprecipitate. OUTCOMES: The patient improved and was discharged after factor replacement therapy, and no further bleeding was reported 1 month after discharge. CONCLUSION: This case report illustrates that the complications of Factor XIII deficiency may include hyperfibrinolysis. Since timely diagnosis of FXIIID is challenging, detailed coagulation factor examinations are needed for definitive diagnosis. It has been suggested that gene testing and antibody testing can help in diagnosis. If ideal treatment is not available, alternative treatment should be provided to reduce bleeding. Lippincott Williams & Wilkins 2022-07-22 /pmc/articles/PMC9302284/ /pubmed/35866832 http://dx.doi.org/10.1097/MD.0000000000029446 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gao, Lingsu Li, Dengju Ding, Meiqi Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title | Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title_full | Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title_fullStr | Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title_full_unstemmed | Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title_short | Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report |
title_sort | hyperfibrinolysis secondary to acquired factor xiii deficiency a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302284/ https://www.ncbi.nlm.nih.gov/pubmed/35866832 http://dx.doi.org/10.1097/MD.0000000000029446 |
work_keys_str_mv | AT gaolingsu hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport AT lidengju hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport AT dingmeiqi hyperfibrinolysissecondarytoacquiredfactorxiiideficiencyacasereport |